Online desk
Clinical trials of the ticker, co-produced by Pfizer, a leading US pharmaceutical company, and Bioentech, a German company, are continuing. Producers of optimism so far. They want to bring the vaccine to the market next October if they get permission to market.Vaccines produced in the United States and Germany began being tested on humans on May 5. They have already started a comprehensive study. And they want to market it quickly. Pfizer and Bioentech said they would conduct worldwide surveys to evaluate their own inventions. Permission will be sought to supply 100 million doses of the vaccine by the end of 2020 and 1.3 billion doses by the end of 2021. In an interview with Time magazine, Albert Borla, Pfizer's chief executive, said they hoped the FDA would approve the vaccine by October. Patients will be initially given two doses of the vaccine to boost immunity. As a result, about 50 million people will get the first 100 million doses. The vaccine will be tested on about 30,000 people in 120 places around the world. Especially in areas where there is a high prevalence of corona.
No comments:
Post a Comment